In a phase II study of midostaurin monotherapy, 14 out of 20 patients with relapsed/refractory AML or myelodysplastic syndrome with FLT3 activating mutations achieved approximately 50% reduction in peripheral blasts [150]. This evidence concerns the gene FLT3 and acute myeloid leukemia.